Multiple Myeloma – An Introduction - Cancer.Net
NCT03412565: Phase 2 - Subcutaneous Daratumumab in Combination With Standard MM Regimens - PLEIADES
NCT03757221: Phase 2 - IFM 2018-02 - Ixazomib -Daratumumab Without Dex in Elderly RRMM (IDARA)
How can myeloma patients protect themselves from infections? International Myeloma Foundation
NCT03729804: Phase 3: KRd Versus VRd in Patients With Newly Diagnosed Multiple Myeloma (COBRA)
NCT03672318: Phase 1: Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma
NCT03435796: Phase 2/3: Long-Term Follow-up for Participants Treated With Gene-Modified T Cells
NCI National Cancer Institute: Immunotherapy: How the Immune System Fights Cancer
NCT03606577: Phase 2-IFM 2018 - 04 - Quadruplet Induction & Consolidation + Tandem ASCT Hi Risk NDMM
NCT03428373: Phase 2: Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma (RithMM)
NCT03752541: Allogeneic T-cells with Anti-BCMA CAR - BCMA-UCART in RRMM - Chinese study
FDA Approved for RRMM: Elotuzumab (Empliciti) with Pomalidomide and dexamethasone (Pd)
NCT03758417: Phase 2 - LCAR-B38M CAR-T Cells Against BCMA in Chinese relapsed Myeloma (CARTIFAN - 1)
NCT03716856: Phase 1 - CAR-BCMA T in Patients With Refractory or Relapsed Multiple - Chinese study
NCT03502577: Phase 1 - BCMA-Specific CAR T-Cells Combined With Gamma Secretase Inhibitor (JSMD194)
NCT03773107: Phase 1/2: LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib RRMM
IMF - International Myeloma Foundation: Patient Handbook
IMF - International Myeloma Foundation: Understanding Freelite and Hevylite Tests
IMF - International Myeloma Foundation: Understanding Fatigue